Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin A Gartrell

Showing results (1-10 of 52) with videos related to

Pageof 6
Sort By:
Nature Reviews. Clinical Oncology|May 14, 2014
Managing bone metastases and reducing skeletal related events in prostate cancerBenjamin A Gartrell, Fred Saad
Expert Opinion on Emerging Drugs|November 8, 2013
Emerging drugs for urothelial carcinomaBenjamin A Gartrell, Guru Sonpavde
Therapeutic Advances in Urology|October 8, 2015
Abiraterone in the management of castration-resistant prostate cancer prior to chemotherapyBenjamin A Gartrell, Fred Saad
Current Opinion in Urology|August 29, 2014
Pathologic fracture in patients with metastatic prostate cancerBenjamin A Gartrell, Fred Saad
European Urology|September 16, 2014
Clinical decision making in castration-resistant prostate cancer according to baseline prostate-specific antigen: are we measuring disease burden or disease biology?Benjamin A Gartrell, Matthew D Galsky
The New England Journal of Medicine|September 24, 2025
Nonoperative Management of Mismatch Repair-Deficient TumorsChristopher D Jakubowski, Amit Verma, Benjamin A Gartrell
Expert Opinion on Emerging Drugs|May 31, 2017
Emerging drugs for urothelial (bladder) cancerKerwin Cumberbatch, Tianfang He, Zachary Thorogood, et al.
Urologic Oncology|April 20, 2012
The follicle-stimulating hormone receptor: a novel target in genitourinary malignanciesBenjamin A Gartrell, Che-kai Tsao, Matthew D Galsky
Urologic Oncology|October 29, 2017
Update of systemic immunotherapy for advanced urothelial carcinomaBenjamin A Gartrell, Tianfang He, Janaki Sharma, et al.
Current Urology Reports|June 21, 2025
Packing the Punch: Current and Emerging Treatment Strategies in Metastatic Castration-Sensitive Prostate CancerSteven P Troy, Christopher D Jakubowski, Benjamin A Gartrell
Pageof 6

Showing results (1-10 of 52) with videos related to

Sort By:
Pageof 6
Nature Reviews. Clinical Oncology|May 14, 2014
Managing bone metastases and reducing skeletal related events in prostate cancerBenjamin A Gartrell, Fred Saad
Expert Opinion on Emerging Drugs|November 8, 2013
Emerging drugs for urothelial carcinomaBenjamin A Gartrell, Guru Sonpavde
Therapeutic Advances in Urology|October 8, 2015
Abiraterone in the management of castration-resistant prostate cancer prior to chemotherapyBenjamin A Gartrell, Fred Saad
Current Opinion in Urology|August 29, 2014
Pathologic fracture in patients with metastatic prostate cancerBenjamin A Gartrell, Fred Saad
European Urology|September 16, 2014
Clinical decision making in castration-resistant prostate cancer according to baseline prostate-specific antigen: are we measuring disease burden or disease biology?Benjamin A Gartrell, Matthew D Galsky
The New England Journal of Medicine|September 24, 2025
Nonoperative Management of Mismatch Repair-Deficient TumorsChristopher D Jakubowski, Amit Verma, Benjamin A Gartrell
Expert Opinion on Emerging Drugs|May 31, 2017
Emerging drugs for urothelial (bladder) cancerKerwin Cumberbatch, Tianfang He, Zachary Thorogood, et al.
Urologic Oncology|April 20, 2012
The follicle-stimulating hormone receptor: a novel target in genitourinary malignanciesBenjamin A Gartrell, Che-kai Tsao, Matthew D Galsky
Urologic Oncology|October 29, 2017
Update of systemic immunotherapy for advanced urothelial carcinomaBenjamin A Gartrell, Tianfang He, Janaki Sharma, et al.
Current Urology Reports|June 21, 2025
Packing the Punch: Current and Emerging Treatment Strategies in Metastatic Castration-Sensitive Prostate CancerSteven P Troy, Christopher D Jakubowski, Benjamin A Gartrell
Pageof 6